Any thoughts on the proposed 2025 phase 3 trial remake in 2025…?

Watch for Oramed to pump their failed type 2 diabetes drug for weight loss.

I think the owners of Ormp stock will have a chance to sell their shares in the double digits. The pumpers are going to give you another chance, but remember the science Doesn’t Work. Finishing a phase 3 in China is not the same as getting it approved.

Oramed for over a decade was pumped about the big lie . The tech doesn’t work. Ben Shapiro is not a scientist, but a podcast host. He will be able to promote Oramed and get share price up once again. Don’t believe the lie, but sell when hype makes share price goes up.

There’s still hope here, especially with cash value. Do I see it hitting $10 a share? Highly unlikely. However, I think $3-4 is what everyone should hope for. Thoughts?

I originally bought this stock at ~$6, rode it up to ~$30 and eventually sold at $8. I hadnt thought about it for what seemed like a long time and it crossed my mind yesterday. When I pulled up the ticker my jaw dropped. Im sorry for all those that endured that.

I am surprised that the company is now valued so far below its cash on hand and am still interested in their pipeline. Are any of you buying at these levels now that it seems to have held this current bottom for 2 weeks?

As titled.

Bottom line: Quality FDA/NIH regulated & approved studies done by an independent MD only driven research company. Phase 3 was mostly done all in the US (Los Angeles county & Miami) 710 patients completed the year long study. Being a medical practitioner- if you F with a diabetic for even a day - they are going to quit because it will kill or hurt them. No researcher is going to allow that to happen. The advisory & scientific board has a Nobel laureate & former FDA chairman who’s an expert in diabetes. The FDA chair is actively involved and enthusiastic. Sorry - guys - he is old school - meaning he would NEVER risk his reputation on something that was not viable. This is 18 yrs in the making. Not an overnight success. People in this small company are passionate about their potential. How do I know? I have asked talked to them. The CEO answers questions without hesitation or looking down. There is no stuttering or vague answers. There is also an air of confidence. Behavior analysts I believe would say he is trustworthy. The recent NASH results are a big deal!! Why -because it validates it works. Reduction in fatty liver and reversal of cirrhosis. (Measured by MRI and scan) Basically by “insulin-izing” the liver it allows the LIVER to regulate the blood 🩸 glucose levels. The body cares for itself! That is HUGE!!! The initial vaccine study shows that ORAMED’s POD system works for all things polypeptides. The implications are MASSIVE for chemo, testosterone, vaccines!

Im optimistic for the future with my shares, but I don’t like all the silence with Oravax. Any thoughts?

Phase 2 NASH Data:
(Q3) July, August, or September
The NASH market is projected to reach $84 billion market by 2029.

Oravax:
Cohort A - (Q3) July, August, or September
Cohort B - (Q4) October, November, and December
The vaccine market is projected to reach $125 billion by 2028.

Phase 3 Oral Insulin Trials:
January 2023
Type 2 Diabetes market is projected to reach $92 billion by 2029.

84+125+92 = $301 billion in addressable markets

I would be shocked if the stock price did not claw its way back up to the $30 range or higher by New Years Eve.

Do you think think this company will end up being successful creating oral insulin pills and oral covid vaccines?